Related Experiment Video
Updated: Jul 24, 2025
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
Published on: June 8, 2020
Colorectal cancer screening: The role of MT-sDNA testing
1At the time this article was written, Burton James Mollman practiced in family medicine at Baker Family Medicine in Bismarck, N.D. The author discloses that he is a paid medical advisory board member for Exact Sciences. The author attests that this article is independent of any relationship with Exact Sciences. The author has disclosed no other potential conflicts of interest, financial or otherwise.
Abstract:
Because an estimated 10.5% of new colorectal cancer (CRC) cases occur in patients under age 50 years, the US Preventive Services Task Force in 2021 recommended CRC screening for adults ages 45 to 49 years. The prevalence of up-to-date CRC screening with any recommended test among patients age 45 years and older in the United States is only 59% in 2023, indicating that existing screening practices are ineffective. Screening options now include invasive and noninvasive measures. Multi-target stool DNA (MT-sDNA) testing is a simple, low-risk, noninvasive test that provides excellent sensitivity and specificity, is cost-effective, and may increase patient screening rates. CRC screening guideline recommendations and alternative screening methods may help improve patient outcomes and reduce morbidity and mortality. This article describes MT-sDNA testing, its effectiveness, recommended use, and potential expanding role as a screening option.
